Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer

Abstract

Background:Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).Methods:Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.Results:Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ⩾50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ⩾50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.Conclusion:Abiraterone has important antitumour activity in men with CRPC even after DES exposure.

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer’

“…Our report observed PSA declines ⩾50% in 28.4% of 81 patients treated with AA after DES and docetaxel and radiological responses in 25% of patients (Omlin et al , 2013). The differences of these two reports could be explained by the post hoc nature of the analyses and the differences in use of steroids.…”

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

“…Beside NAAs, with CAB a novel taxane has also entered clinical practice 10,11. CAB has been approved for the treatment of mCRPC in the post-docetaxel setting as a 2 nd line treatment and is currently investigated within the FIRSTANA trial as 1 st line treatment option at different dose levels.…”

Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series

“…[26][27][28] In patients who were treated with ENZ after treatment with docetaxel had failed, the use of third-line AA was associated with efficacy that was inferior to the reverse sequence analyzed herein. [29][30][31] Current guidelines do not suggest any specific agent after docetaxel and either AA or ENZ as second-line therapy. Current research is on optimizing the better sequence or the best combination of hormonal agents after first-line docetaxel treatment.…”